Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- Annual Re-Pricing Key Focus Issue for Japan Pharma Trade Group in FY2018
March 16, 2018
- Hodanren Opposes Generic Use Requirement for Welfare Recipients
February 23, 2018
- JPMA to Compile Counterproposal for New PMP Scheme ASAP
February 16, 2018
- Astellas Becomes 1st Japan Maker to Join PhRMA Leadership
February 14, 2018
- Private Univ. Group Encourages “Single-Product, Single-Price” Deals in Response to New Distribution GL, Tougher Medical Fee Cut Rules
February 9, 2018
- “Unprecedented Reforms to Take Place as a Result of Chuikyo’s Leadership”: JMA Pres. Yokokura
February 8, 2018
- Japan Could Miss Out on Wave 1 of Drug Development, Re-Do and Do Right on PMP: PhRMA
January 30, 2018
- Japan Pharma Leader Says Pricing Overhaul Would Not Expand Drug Lag
January 18, 2018
- Exclude 50 Yen or Lower Price Generics from “Off-Year” Re-Pricing: JGA Chief
January 15, 2018
- Pharma Leaders Air Bleak Outlook on New PMP Scheme at New Year’s Reception
January 10, 2018
- JPMA to Call for Improvements in PMP-Eligibility Criteria, Company Requirements: Chief
December 22, 2017
- Continued Discussions Needed for PMP-Eligible Products, Company Criteria: FPMAJ/JPMA
December 22, 2017
- PhRMA/EFPIA Rap Japan’s Drug Pricing Reform, Warn of Grave Consequences
December 21, 2017
- Novo Pres. Bech Re-Elected as EFPIA Japan Chief
December 18, 2017
- GHIT Fund’s New 5-Year Strategic Plan Aims to Win Approval of 2 Products
December 12, 2017
- PhRMA/EFPIA to Govt: Make Major Changes to Drug Pricing Proposal, It Will Tarnish Japan’s Reputation
December 11, 2017
- PhRMA Stands Pat on PMP Push, Says Minor Modification to Govt Proposal “Far from Sufficient”
December 8, 2017
- PhRMA Japan Chief “Shocked” by Govt’s PMP Plan, Doesn’t Want It Institutionalized as Proposed
November 27, 2017
- Hodanren Petitions Health and Finance Ministers to “Abolish the Price Maintenance Premium”
November 22, 2017
- Patrik Jonsson to Remain PhRMA Japan Chief as Pricing Reform Debate Continues
November 20, 2017
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…